Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand

Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand

Background: In Thailand, early vaccination initiatives for SARS-CoV-2 relied on CoronaVac (Sinovac Life Sciences) and ChAdOx1 (Oxford–AstraZeneca) vaccines. However, the data of immunogenicity of these two vaccines in Thai populations is limited. This real time, head-to-head comparative study was co...

Full description

Bibliographic Details
Main Authors: Sayamon Hongjaisee, Kriangkrai Chawansuntati, Patumrat Sripan, Kritsadee Rattanathammethee, Supachai Sakkhachornphop, Romanee Chaiwarith, Tavitiya Sudjaritruk, Khuanchai Supparatpinyo, Jiraprapa Wipasa
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Vaccine: X
Subjects:
Coronavirus disease (COVID-19)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
CoronaVac
ChAdOx1
Neutralizing antibodies
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136223000463

Internet

http://www.sciencedirect.com/science/article/pii/S2590136223000463

Similar Items